B of A Securities Downgrades Sherwin-Williams to Neutral, Lowers Price Target to $292
B of A Securities analyst Steve Byrne downgrades Sherwin-Williams (NYSE:SHW) from Buy to Neutral and lowers the price target from $313 to $292.
B of A Securities Initiates Coverage On Enhabit with Underperform Rating, Announces Price Target of $16
B of A Securities analyst Joanna Gajuk initiates coverage on Enhabit (NYSE:EHAB) with a Underperform rating and announces Price Target of $16.
B of A Securities Downgrades Veritone to Neutral, Lowers Price Target to $10
B of A Securities analyst Koji Ikeda downgrades Veritone (NASDAQ:VERI) from Buy to Neutral and lowers the price target from $14 to $10.
Barclays Maintains Overweight on Certara, Lowers Price Target to $24
Barclays analyst Luke Sergott maintains Certara (NASDAQ:CERT) with a Overweight and lowers the price target from $25 to $24.
Stifel Downgrades Atara Biotherapeutics to Hold, Lowers Price Target to $5
Stifel analyst Benjamin Burnett downgrades Atara Biotherapeutics (NASDAQ:ATRA) from Buy to Hold and lowers the price target from $16 to $5.
Wells Fargo Maintains Overweight on Mastercard, Lowers Price Target to $400
Wells Fargo analyst Donald Fandetti maintains Mastercard (NYSE:MA) with a Overweight and lowers the price target from $450 to $400.
Wells Fargo Maintains Equal-Weight on Discover Financial, Lowers Price Target to $103
Wells Fargo analyst Donald Fandetti maintains Discover Financial (NYSE:DFS) with a Equal-Weight and lowers the price target from $130 to $103.
Wells Fargo Maintains Overweight on Capital One Financial, Lowers Price Target to $130
Wells Fargo analyst Donald Fandetti maintains Capital One Financial (NYSE:COF) with a Overweight and lowers the price target from $160 to $130.
Wells Fargo Maintains Overweight on American Express, Lowers Price Target to $190
Wells Fargo analyst Donald Fandetti maintains American Express (NYSE:AXP) with a Overweight and lowers the price target from $215 to $190.
Credit Suisse Maintains Outperform on Kura Oncology, Raises Price Target to $29
Credit Suisse analyst Tiago Fauth maintains Kura Oncology (NASDAQ:KURA) with a Outperform and raises the price target from $27 to $29.